TwoStep Therapeutics raised $6.5M in a seed round led by NFX to advance a broadly applicable targeting platform for solid tumors

Jun 25, 2024•about 1 year ago

Amount Raised

$6.5 Million

Round Type

seed

San CarlosBiotechnology

Investors

Arcadia Investment PartnersGc&H InvestmentsAlexandria Venture Investments2048 VenturesNfx

Description

TwoStep Therapeutics, a biotechnology company developing new targeted therapeutics for solid tumors, officially launched following a successful $6.5 million seed round led by NFX, with other investors including 2048 Ventures, Alexandria Venture Investments, Cooley’s affiliated fund GC&H Investments, and the family office of the founder of Arcadia Investment Partners. The financing will be used to advance TwoStep’s therapeutic pipeline of solid tumor-targeting therapies, with an initial focus on targeted cytotoxic drug delivery and immunotherapy.

Company Information

Company

TwoStep Therapeutics

Location

San Carlos, California, United States

About

TwoStep Therapeutics is pioneering a multi-targeting platform to advance a pipeline of targeted therapies that are broadly applicable across solid tumors. With this approach, the company aims to transform cancer treatment by extending precision medicines to more diverse tumor types and patient populations, for which few options exist. TwoStep Therapeutics was co-founded by CEO, Caitlyn Miller, in collaboration with world-renowned academic entrepreneurs at Stanford University: Jennifer Cochran, Ronald Levy, and Nobel Laureate Carolyn Bertozzi.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns